These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
73 related articles for article (PubMed ID: 22437319)
41. Potential utility of mutant oncogene-specific antibodies in melanoma. Murphy MJ; Elaba Z Am J Dermatopathol; 2014 Jun; 36(6):522-3. PubMed ID: 23823028 [No Abstract] [Full Text] [Related]
42. Amplification of N-myc oncogene in human melanoma cells. Bauer J; Sokol L; Stríbrná J; Kremen M; Krajsová I; Hausner P; Hejnar P Neoplasma; 1990; 37(3):233-8. PubMed ID: 2370914 [TBL] [Abstract][Full Text] [Related]
43. Association of EGFR gene fragments with nuclear matrix proteins in high and low metastatic melanoma cell lines. Wang ZH; Ding MX; Jin ML; Cheng-Chew SB; Yun JP; Wu BQ; Chew EC Anticancer Res; 1999; 19(5B):4349-52. PubMed ID: 10628399 [TBL] [Abstract][Full Text] [Related]
44. Analysis of KIT expression and gene mutation in human acral melanoma: with a comparison between primary tumors and corresponding metastases/recurrences. Dai B; Cai X; Kong YY; Yang F; Shen XX; Wang LW; Kong JC Hum Pathol; 2013 Aug; 44(8):1472-8. PubMed ID: 23528861 [TBL] [Abstract][Full Text] [Related]
45. Two independent amplification events on chromosome 7 in glioma: amplification of the epidermal growth factor receptor gene and amplification of the oncogene MET. Wullich B; Sattler HP; Fischer U; Meese E Anticancer Res; 1994; 14(2A):577-9. PubMed ID: 8017863 [TBL] [Abstract][Full Text] [Related]
46. Next-generation sequencing in advanced Chinese melanoma reveals therapeutic targets and prognostic biomarkers for immunotherapy. Huang F; Li J; Wen X; Zhu B; Liu W; Wang J; Jiang H; Ding Y; Li D; Zhang X Sci Rep; 2022 Jun; 12(1):9559. PubMed ID: 35688842 [TBL] [Abstract][Full Text] [Related]
47. Time-varying pattern of recurrence risk for localized melanoma in China. Wen X; Li D; Zhao J; Li J; Yang T; Ding Y; Peng R; Zhu B; Huang F; Zhang X World J Surg Oncol; 2020 Jan; 18(1):6. PubMed ID: 31901239 [TBL] [Abstract][Full Text] [Related]
48. The General Expression Analysis of WTX Gene in Normal and Cancer Tissues. Zhang YY; Wang QM; Niu HL; Liu X; Zhang QL Pathol Oncol Res; 2017 Apr; 23(2):439-446. PubMed ID: 28032309 [TBL] [Abstract][Full Text] [Related]
49. Prognostic and Clinicopathologic Associations of BRAF Mutation in Primary Acral Lentiginous Melanoma in Korean Patients: A Preliminary Study. Hong JW; Lee S; Kim DC; Kim KH; Song KH Ann Dermatol; 2014 Apr; 26(2):195-202. PubMed ID: 24882974 [TBL] [Abstract][Full Text] [Related]
50. NRAS mutations in primary and metastatic melanomas of Japanese patients. Uhara H; Ashida A; Koga H; Ogawa E; Uchiyama A; Uchiyama R; Hayashi K; Kiniwa Y; Okuyama R Int J Clin Oncol; 2014; 19(3):544-8. PubMed ID: 23739925 [TBL] [Abstract][Full Text] [Related]
51. The absence of the ERBB4 hotspot mutations in melanomas in patients from southern China. Zhou QM; Li W; Guan YX; Zhang X; Chen XC; Ding Y; Wen XZ; Peng RQ; Yan SM; Zhang XS Chin J Cancer; 2013 Jul; 32(7):410-4. PubMed ID: 23237222 [TBL] [Abstract][Full Text] [Related]
52. The classification of cutaneous melanoma. Duncan LM Hematol Oncol Clin North Am; 2009 Jun; 23(3):501-13, ix. PubMed ID: 19464599 [TBL] [Abstract][Full Text] [Related]
53. The mutation profiles of common oncogenes involved in melanoma in southern China. Zhou QM; Li W; Zhang X; Chen YB; Chen XC; Guan YX; Ding Y; Wen XZ; Xia Q; Zhou Q; Peng RQ; Hou JH; Zhu XF; Zeng YX; Zhang XS J Invest Dermatol; 2012 Jul; 132(7):1935-7. PubMed ID: 22437319 [No Abstract] [Full Text] [Related]
54. Mutations in ERBB4 may have a minor role in melanoma pathogenesis. Manca A; Lissia A; Cossu A; Rubino C; Ascierto PA; Stanganelli I; Palmieri G J Invest Dermatol; 2013 Jun; 133(6):1685-7. PubMed ID: 23340734 [No Abstract] [Full Text] [Related]
55. Mutated ERBB4: a novel drug target in metastatic melanoma? Kurppa K; Elenius K Pigment Cell Melanoma Res; 2009 Dec; 22(6):708-10. PubMed ID: 19735458 [No Abstract] [Full Text] [Related]